MONTREAL, April 4 /CNW Telbec/ - Haemacure Corporation (TSX : HAE), a
Montreal-based specialty biotherapeutics company, announced today that
Mr. Joseph A. Akers was appointed to its Board of Directors. Mr. Akers will
also be a member of the Audit Committee.
Mr. Akers enjoyed a 30-year plus successful career at Bayer Healthcare, a
renowned pharmaceutical multinational company. Mr. Akers was, until the
beginning of 2007, President of the Bayer Healthcare Hematology/Cardiology
Business Unit (formerly known as Biological Products Division).
"We are delighted to welcome Joe to Haemacure's Board of Directors," said
Joseph Galli, Chairman and Chief Executive Officer. "While at Bayer
Healthcare, Joseph has acquired highly valuable experience in the development,
production and marketing of plasma protein products that will certainly prove
beneficial to Haemacure in all aspects of its new development plan."
"Joining Haemacure's Board of Directors at this stage, after a successful
financing round last January and the announcement of a new development
strategy, is certainly very exciting," commented Mr. Akers. "I believe the
strategy to exploit as much as possible of the protein content of its
plasma-derived intermediates can prove very profitable for Haemacure."
Mr. Akers started his career in the industry by joining Cutter
Laboratories in California in 1970. In 1974, Bayer A.G. acquired Cutter, which
later became Bayer's Biological Products Division. Over the years, Mr. Akers
held various senior and executive positions in corporate finance and
administration at Bayer in Europe and the United States. In 1999, Mr. Akers
was appointed Executive Vice-President and Chief Administrative and Financial
Officer of Bayer Corporation in Pittsburgh, Pa. and in 2004 was appointed
President of Bayer Healthcare's Hematology/Cardiology Business Unit.
Haemacure also announced that Mr. Joseph Galli, Chairman and Chief
Executive Officer of Haemacure, will present at the five following investors
- Equities Spring Conference 2007, on April 20, 2007 at 7:30 am at
The Yale Club, 50 Vanderbilt Ave., New York NY,
- The Corporate Forum, on April 23, 2007 at noon at the New York Yacht
Club, 37 West 44th Street, New York NY,
- The Corporate Forum, on April 24, 2007 at noon at the Langham Hotel,
250 Franklin Street, Boston MA,
- The Corporate Forum,on April 25, 2007 at 11:45 am at the Four Seasons
Philadelphia, One Logan Square, Philadelphia PA and
- Rodman & Renshaw Healthcare Conference on May 14 and 15, 2007, at
Le Méridien Beach Plaza Hotel, Monte Carlo, Monaco.
Haemacure Corporation is a specialty biotherapeutics company focused on
developing and commercializing premium human therapeutic proteins. Haemacure
utilizes its proprietary plasma protein extraction technology to develop next
generation products, including hemostats for surgical use. The lead product
candidate, Hemaseel(TM)HMN, an all human fibrin sealant, is in late stage
clinical development for biosurgical applications. The second product, an
all-human thrombin, a component of fibrin sealant, also has applications as a
stand-alone product in the expanding biosurgical market. Follow-on development
will focus on biomaterial combinations and drug delivery in select therapeutic
areas. Haemacure will develop partnerships to advance specialty proteins that
it has recently identified in its plasma-derived intermediates to address
unmet medical needs of patients. Haemacure also operates offices in Sarasota,
Florida through a wholly-owned subsidiary. The Corporation is traded under
stock symbol HAE on the TSX.
Certain of the statements contained in this news release are
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown. Some examples of known risks are: the impact
of general economic conditions, general conditions in the biotech industry,
changes in the regulatory environment in the jurisdictions in which Haemacure
Corporation does business, stock market volatility, fluctuations in costs, and
changes to the competitive environment due to consolidation or otherwise.
Consequently, actual future results may differ materially from the anticipated
results expressed in the forward-looking statements. Haemacure Corporation
disclaims any intention or obligation to update these statements.
For further information:
For further information: Haemacure Corporation: Joseph Galli, Chairman
and CEO, (514) 990-7074